Reconstruction of tumor-associated

Reconstruction of tumor-associated systems Redeeming validity is tailored on the relation of modular communication to the objective features of the tumor compartment, the reconstructible evolutionary (modular) systems. Robustness The BMS-907351 nmr inherent property of a system to maintain normal performance despite external and internal perturbations. Separated or separating ‘social’ tumor systems The possibility for redeeming novel validity by modular therapies is indicative for the existence of biologically separated or separating ‘social’ systems, i.e. in our context, metastatic tumors: Tumors constitute a solitary world with an internal

context. References 1. Hait WN (2009) Targeted cancer therapeutics. Cancer Res 69:1263–1267PubMedCrossRef 2. Hochhaus A (2008) First-Line management of CML: a state of the art review. J Natl Compr Canc Netw 6(Suppl 2):S1–S10PubMed 3. Sonnenschein C, Soto AM (2008) Theories of carcinogenesis: an emerging perspective. Semin Cancer Biol 18:372–377PubMedCrossRef 4. Trosko JE (2007) Gap junctional learn more intercellular communication as a biological “Rosetta stone” in understanding, in a systems biological manner, stem cell behavior, mechanisms of epigenetic toxicology, chemoprevention and chemotherapy. J Membr Biol 218:93–100PubMedCrossRef 5. Aebersold R, Auffray C, Baney E, Barillot E, Brazma

A, Brett C, Brunak S, Butte A, Califano A, Celis J, Cufer T, Ferrell J, Galas D, Gallahan D, Gatenby R, Goldbeter A, Hace N, Henney A, Hood L, Iyengar R, Jackson V, Kallioniemi O, Klingmuller U, Kolar P, Kolch W, Kyriakopoulou C, Laplace F, Lehrach H, Marcus F, Matrisian L, Nolan G, Pelkmans L, Potti A, Sander C, Seljak M, Singer D, Sorger P, Stunnenberg H, Superti-Furga G, Uhlen M, Vidal M, Weinstein J, Wigle D, Williams M, Wolkenhauer O, Zhivotovsky B, Zinovyev A, Zupan B (2009) Report on EU-USA workshop: how

systems biology can advance cancer research (27 October 2008). Mol Oncol 3:9–17PubMedCrossRef 6. Reichle A, Vogt T (2008) Systems biology: a therapeutic target Fenbendazole for tumor therapy. Cancer Microenviron 1:159–170PubMedCrossRef 7. Kirschner M, Gerhart J (1998) Evolvability. Proc Natl Acad Sci USA 95:8420–8427PubMedCrossRef 8. Witz IP (2008) Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res 100:203–229PubMedCrossRef 9. Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA, Xiang R (2006) Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116:2132–2141PubMedCrossRef 10. Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, selleck chemicals llc Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, Kranz DM, Schreiber H (2007) Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 204:49–55PubMedCrossRef 11.

Comments are closed.